Overview

• Eli Lilly reports a shortage of Zepbound, a weight loss drug, with limited availability expected to continue into June.
• The shortage also affects Mounjaro, used for diabetes, as both drugs share the active ingredient tirzepatide.
• Patients struggle to find available doses, with some facing the risk of having to restart treatment.
• Lilly plans to open a new manufacturing facility in North Carolina by year's end to boost drug production.
• The shortage has forced some doctors to switch patients to alternative medications, impacting treatment continuity.